Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Company Profile and bullboard matches:

AMXX , NPNAF
Sort by: Date|Relevance

Neovasc Shares Climb 80% Upon FDA Premarket Approval Filing for Refractory Angina Device

Shares of specialty cardiovascular medical device company Neovasc Inc. opened more than 100% higher after the firm reported that it submitted a Premarket Approval application to the FDA for its Neovasc Reducer device for use in the treatment of refractory angina. This...

The New Cannabis & CBD Therapy for PTSD

This podcast is part of our StockTalk Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public cannabis marketplace. There are around eight million people in the U...

Torrid Advances in Gold ETFs Warrant Caution

Michael Ballanger explains how he is reacting to the advances in the gold ETFs. Given the torrid advance in gold (GLD [SPDR Gold Shares]) and the leveraged miner ETFs (NUGT [Direxion Daily Gold Miners Index Bull 3x]/JNUG [Direxion Daily Junior Gold Miners In...

Near-Term Risk in Gold is Increasing

Last week was another strong one for the precious metals sector. Gold gained a whopping $51/oz or 3.5%. The gold stocks (GDX, GDXJ) advanced by roughly 6%. Silver gained 4%. Momentum in the sector began to build once Gold surpassed resistance at $1420-$1425/oz. We had ...

Correction in Gold Stocks Continues

Several weeks ago both Gold and gold stocks hit major resistance after strong but extended moves. A correction or pause was to be expected. Clearly, we can now say, the sector is in correction mode. Corrections tend to have three legs: a simple down up down or A-B-C patter...

After An Extremely Rare Move In Bonds, How Have Stocks And Bonds Performed In The Past?

LEARNING FROM HISTORICAL MARKET FACTS When investors are concerned about future economic outcomes, they often migrate toward more defensive-oriented long-term U.S. Treasury bonds (TLT). The recent surge in demand for defensive bonds caused an extremely rare and extended loo...

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. Yesterday afternoon, Dermira Inc. (DERM:NASDAQ) , a biopharmaceu...

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. This morning, Hamilton, Bermuda based biopharmaceutical company ...

NexTech AR Solutions Update After Major Ramp-Up

Technical analyst Clive Maund provides an update on the prospects for this technology firm. While clivemaund.com is primarily a resource stocks website, we recognize that investing is an opportunity cost game, and for this reason we have no problem buying a tech stock...

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment

Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. This morning biopharmac...
1 2 3 4 5 6 7 8 9 10 ...